Opto Circuits' group company, Cardiac Science, has launched newest automated external defibrillator (AED) to the US and Canadian markets, representing a technological milestone in the AED industry and high anticipation from its loyal customers.

The Powerheart G5 is the first FDA-cleared AED to combine fully automatic shock delivery, dual-language functionality, variable escalating energy, and fast shock times to help save a sudden cardiac arrest (SCA) victim's life. SCA is the No 1 global cause of death with 17.3 million deaths each year, according to the American Heart Association.

Vinod Ramnani, chairman and managing director, said, “The North American AED market has yearned for an AED of this technology, scope, and importance. We have seen the impact of this product when we launched it in Europe back in 2012 with immediate market share, adoption, and demand.”

Along with its sister AED, the Powerheart G3, the Powerheart G5 is designed to enable rescuers to swiftly provide effective, life-saving therapy to aid a person who has suffered SCA, a condition in which the heart suddenly stops beating due to irregularities in its electrical system.
“As more and more countries recognize the threat posed by SCA, legislation and public attitudes are steering buying decisions. This, in turn, has allowed our company to maintain price-points as customers want AEDs that our easy to use, ready for operation, and feature advanced technology,” added Ramnani.

Opto Circuits (India) Ltd. (OCI) is a vertically integrated multinational medical technology group that specializes in primary, acute and critical care products for the global markets. Group companies such as Cardiac Science, Criticare, Eurocor, Mediaid, AMDL and Unetixs Vascular are leaders in vital signs monitors, emergency cardiac care equipment, vascular treatments and sensing technologies.